IDH1 and central nervous system cancer: APOLLO also demonstrated strong discriminative capability in resolving clinically relevant glioma methylation subtypes, specifically distinguishing between the G-CIMP-high and G-CIMP-low molecular subtypes within IDH1-mutant gliomas.